SCHEMBL23928899

SCHEMBL23928899

Cn1cc(Br)c2cc(C#N)cnc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.45
PTGER4 P35408 1/20 0.43
ABL1 P00519 2/20 0.36
AURKA O14965 1/20 0.36
JAK2 O60674 1/20 0.36
PAK4 O96013 1/20 0.36
NTRK1 P04629 1/20 0.36
LCK P06239 1/20 0.36
FYN P06241 1/20 0.36
CSF1R P07333 1/20 0.36
RET P07949 1/20 0.36
IGF1R P08069 1/20 0.36
MET P08581 1/20 0.36
PDGFRB P09619 1/20 0.36
PIM1 P11309 1/20 0.36
FGFR1 P11362 1/20 0.36
PRKACA P17612 1/20 0.36
FLT3 P36888 1/20 0.36
MAPK8 P45983 1/20 0.36
MAPK9 P45984 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31020829 1.00 HTT (0.45) HTTPTGER4ABL1AURKAJAK2
SCHEMBL29880693 0.81 PTGER4 (0.43) HTTPTGER4ABL1AURKAJAK2
SCHEMBL14031125 0.81 BRD4 (0.47) HTTPTGER4ABL1AURKAJAK2
SCHEMBL23452230 0.81 PTGER4 (0.43) HTTPTGER4ABL1AURKAJAK2
SCHEMBL27765124 0.79 PTGER4 (0.42) HTTPTGER4ABL1AURKAJAK2
SCHEMBL31370721 0.76 BRD4 (0.35) GSK3BKDM4EBRD4
SCHEMBL25230123 0.76 RORC (0.46) PTGER4RORC
SCHEMBL24330125 0.75 PDK1 (0.36) ABL1AURKAJAK2PAK4NTRK1
SCHEMBL30611189 0.75 PDK1 (0.36) ABL1AURKAJAK2PAK4NTRK1
SCHEMBL15384517 0.75 HSD17B10 (0.42) HTTGSK3BL3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250049036-A1 SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI PI INDUSTRIES LTD. (IN) 2025-02-13 US disclosed
EP-4448494-A1 NOVEL SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI PI Industries Ltd. (IN) 2024-10-23 EP disclosed
EP-3820869-B1 SPIROCHROMANE DERIVATIVES RICHTER GEDEON NYRT (HU) 2023-08-30 EP disclosed
WO-2023112056-A1 NOVEL SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI PI INDUSTRIES LTD. (IN) 2023-06-22 WO disclosed
US-20210330650-A1 SPIROCHROMANE DERIVATIVES RICHTER GEDEON NYRT. (HU) 2021-10-28 US disclosed
CN-112823157-A Spirochroman derivatives 吉瑞工厂 2021-05-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250049036-A1 SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CBR3, C5, CBR1 HTT 4736/4885PTGER4 3777/4885ABL1 2476/4885
US-20210330650-A1 SPIROCHROMANE DERIVATIVES CHRNA7, CHRM3, ADRB3 HTT 2272/4885PTGER4 1310/4885ABL1 4761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.